rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGGGACGTTTGAACACTGAAGCTTTCTTTGGACAA	CASSVEGRLNTEAFF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	45	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-01	01	0	0	7	0	1	3	23	39	45	40	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVEGRLNTEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01		TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCCGATCAAGAGACCCAGTACTTCGGGCCA	CASSADQETQYF	In	VDJ	1	13	0.0028831226436016855	0.004212572909915748	36	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-05	01	3	2	8	2	2	1	23	36	40	38	41			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSADQETQYF+TCRBV09-01+TCRBJ02-05	TCRBV09-01		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGATGGTCTAGACGAGCAGTACTTCGGGCCG	CASSVDGLDEQYF	In	VDJ	1	16	0.0035484586382789974	0.005184705119896306	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	4	8	5	5	0	23	39	-1	44	48			01,02			01,02							Vb 1	CASSVDGLDEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGACAGGCGACCTCCCCTACGAGCAGTACTTCGGGCCG	CASSVGTGDLPYEQYF	In	VDJ	1	33	0.007318695941450432	0.01069345430978613	48	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	1	4	2	0	8	23	-1	46	39	54			01,02										Vb 1	CASSVGTGDLPYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCCCAAGGGGGACAGGGGGCGCAGATACGCAGTATTTTGGCCCA	CASSPRGTGGADTQYF	In	VDJ	1	19	0.00421379463295631	0.006156837329876863	48	TCRBV11	TCRBV11-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	0	4	6	1	19	31	49	37	50														CASSPRGTGGADTQYF+TCRBV11-01+TCRBJ02-03	TCRBV11-01*01	TCRBD01-01*01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATGGAGGGTTGGCCAAACTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	70	0.015524506542470614		49	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	10	0	3	1	9	29	46	53	47	62													Vb 16	X+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTACCCCCCCGGACGGTAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	11	0.002439565313816811		47	TCRBV07	TCRBV07-06	01				TCRBJ02	TCRBJ02-05	01	2	1	7	3	7	4	18	33	44	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCCCGGTACCGGGAGGAGGCGGGGAGCTGTTTTTTGGAGAA	CASSPVPGGGGELFF	In	VDJ	1	23	0.005100909292526059	0.007453013609850939	45	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	8	1	7	7	3	18	30	44	37	47														CASSPVPGGGGELFF+TCRBV07-06+TCRBJ02-02	TCRBV07-06*01	TCRBD02-01*02	TCRBJ02-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTAAGGGACGGCGCTCGGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	23	0.005100909292526059		44	TCRBV07	TCRBV07-05	01				TCRBJ02	TCRBJ02-02	01	1	0	7	8	1	8	19	34	40	35	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-05+TCRBJ02-02	TCRBV07-05*01		TCRBJ02-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAGCTTGCCTACGAGCAGTACTTCGGGCCG	CASSQELAYEQYF	In	VDJ	1	11	0.002439565313816811	0.0035644847699287103	39	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-07	01	0	10	0	2	0	3	23	-1	42	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQELAYEQYF+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCACTAGAGGGGTGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	21	0.004657351962741184		40	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-03	01	7	5	2	1	4	1	23	33	42	37	43				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGCTATGACAGGGGGCCCAGCTGAAGCTTTCTTTGGACAA	CASSQAMTGGPAEAFF	In	VDJ	1	48	0.010645375914836993	0.015554115359688918	48	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	0	6	4	4	23	39	53	43	57														CASSQAMTGGPAEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCTCGCTACCAGGGGAGTTGCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	20	0.004435573297848747		47	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	4	2	2	7	5	19	28	41	35	46													Vb 5.1	X+TCRBV05-01+TCRBJ01-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTACGCCCCGGGGACAGAAGAGACCCAGTACTTCGGGCCA	CASSYAPGTEETQYF	In	VDJ	1	11	0.002439565313816811	0.0035644847699287103	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	0	5	3	8	0	25	38	-1	46	53													Vb 3	CASSYAPGTEETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCCGTGGAGAGCTGGGCCAACGTCCTGACTTTCGGGGCC	CASSAVESWANVLTF	In	VDJ	1	13	0.0028831226436016855	0.004212572909915748	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	5	10	2	5	5	4	25	37	46	42	50													Vb 3	CASSAVESWANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTGTGGGGCGGAGGGGTACTACAATGAGCAGTTCTTCGGGCCA	CASCGAEGYYNEQFF	In	VDJ	1	13	0.0028831226436016855	0.004212572909915748	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	10	0	3	8	3	25	34	48	42	51													Vb 3	CASCGAEGYYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCGACTTGCGGACAGGGCCCACCGGGGAGCTGTTTTTTGGAGAA	CASSDLRTGPTGELFF	In	VDJ	1	33	0.007318695941450432	0.01069345430978613	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	1	3	4	8	2	25	36	52	44	54													Vb 3	CASSDLRTGPTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGATTCGGGACAGGAATAATCAATGAGCAGTTCTTCGGGCCA	CASRFGTGIINEQFF	In	VDJ	1	45	0.00998003992015968	0.01458198314970836	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	6	4	6	25	36	48	40	54													Vb 3	CASRFGTGIINEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTCTAGTCCGTGGTTGTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSPWLYSNQPQHF	In	VDJ	2	57	0.012641383898868928	0.01847051198963059	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	8	4	8	0	1	12	25	34	39	35	51						01,02							Vb 3	CASSSPWLYSNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTCCTTGGGGATTTGGGAGAGACCCAGTACTTCGGGCCA	CASSFLGDLGETQYF	In	VDJ	2	67	0.014859170547793302	0.02171095268956578	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	3	0	8	4	5	6	25	39	48	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFLGDLGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCACCGTAGTGTTTCGTCAGACGATACGCAGTATTTTGGCCCA		Out	VDJ	4	145	0.032157906409403414		49	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-03	01	5	2	7	6	19	0	25	37	-1	56	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCTAGTAGTATAGCGCACGGCCCCTACGAGCAGTACTTCGGGCCG	CASSIAHGPYEQYF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	1	9	0	2	5	1	27	43	51	48	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIAHGPYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCATGACAGGGTCGGGACAGCCCCAGCATTTTGGTGAT	CASSTMTGSGQPQHF	In	VDJ	1	29	0.006431581281880683	0.009397278029812054	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	2	3	7	4	6	27	40	51	44	57			01,02										Vb 17	CASSTMTGSGQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCTTGGGACAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSSWDSSNQPQHF	In	VDJ	1	36	0.007984031936127744	0.011665586519766688	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	5	0	4	0	27	39	-1	43	50			01,02										Vb 17	CASSSWDSSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAAGGGCGGATGGGGCAAGAGACCCAGTACTTCGGGCCA	CASKGRMGQETQYF	In	VDJ	2	59	0.013084941228653803	0.01911860012961763	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	7	5	3	2	1	9	27	37	42	38	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASKGRMGQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAAGGGTGGGAGGTACGAGCAGTACTTCGGGCCG	CASSIKGGRYEQYF	In	VDJ	2	68	0.01508094921268574	0.0220349967595593	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	1	4	7	0	27	41	-1	48	54			01,02										Vb 17	CASSIKGGRYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCGTCGGGATACGCAGTATTTTGGCCCA	CASSRRDTQYF	In	VDJ	2	81	0.017964071856287425	0.02624756966947505	33	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	8	5	6	4	0	27	38	-1	42	45			01,02			01,02							Vb 17	CASSRRDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGATCAACAGGGTACGGCGGGAAACACCATATATTTTGGAGAG	CASSDQQGTAGNTIYF	In	VDJ	1	15	0.00332667997338656	0.004860661049902786	48	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	3	3	4	3	7	23	37	46	40	53													Vb 11	CASSDQQGTAGNTIYF+TCRBV25-01+TCRBJ01-03	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTAATGGCATCACCGATACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	11	0.002439565313816811		56	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	3	6	5	15	5	22	35	53	50	58		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ02-06	TCRBV12	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGAGCGACGGTCAATTCACCCCTCCACTTTGGGAAC	CASRATVNSPLHF	In	VDJ	1	11	0.002439565313816811	0.0035644847699287103	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	7	6	6	7	0	6	24	-1	39	35	45		TCRBV24-01,TCRBV24-or09_02				01,02								CASRATVNSPLHF+TCRBV24-X+TCRBJ01-06	TCRBV24	TCRBD02-01	TCRBJ01-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCWMCCAGACMTCTSTGTACTTSTGTGCCAGCAGGCCGGACGGTACCTACGAGCAGTGCTTCGGGCCG	CASRPDGTYEQCF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	39	unresolved						TCRBJ02	TCRBJ02-07	01	6	1	7	15	3	17	23	34	41	37	58	TCRBV06,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRPDGTYEQCF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCACGGACAGGTAACACAGATACGCAGTATTTTGGCCCA	CASSPRTGNTDTQYF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	4	2	4	3	18	30	41	34	44	TCRBV07,TCRBV11													CASSPRTGNTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AACYSRRGGACTCAGCYRTGTAYTTYTGTGCCAGCAGTCGGGACAGAAACGAGCAGTTCTTCGGGCCA	CASSRDRNEQFF	In	VDJ	1	13	0.0028831226436016855	0.004212572909915748	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	0	5	10	1	4	26	38	46	39	50	TCRBV02,TCRBV12													CASSRDRNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGCCAATTGACACAGATACGCAGTATTTTGGCCCA	CSAPIDTDTQYF	In	VDJ	1	14	0.003104901308494123	0.004536616979909268	36	TCRBV20						TCRBJ02	TCRBJ02-03	01	6	2	8	2	7	0	26	34	-1	41	43		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPIDTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCACCTCGGACAGGGAACATTACGAGCAGTACTTCGGGCCG	CATSDREHYEQYF	In	VDJ	1	14	0.003104901308494123	0.004536616979909268	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	1	3	4	4	5	22	29	41	33	46		TCRBV12-03,TCRBV12-04												CATSDREHYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGTAGTGGGTTAAGGCCTGAGTGAAAGACCTATGGCTACACCTTCGGTTCG	CASSSGLRPE*KTYGYTF	Stop	VDJ	1	14	0.003104901308494123		54	unresolved						TCRBJ01	TCRBJ01-02	01	6	0	9	4	4	20	24	35	42	39	62	TCRBV12,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGLRPE*KTYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCGGCCGGGACAGTTCCTACGAGCAGTACTTCGGGCCG	CASSGRDSSYEQYF	In	VDJ	1	15	0.00332667997338656	0.004860661049902786	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	1	5	1	26	37	49	42	50	TCRBV09,TCRBV12													CASSGRDSSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGGGGACTCRGCCSTGTATSTCTGTGCCAGCAGCGAAATAATTAGGCTGGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	16	0.0035484586382789974		50	unresolved						TCRBJ01	TCRBJ01-02	01	6	1	8	4	16	5	22	32	51	48	56	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCTCCCGGGACAGGGGGCACTATGGCTACACCTTCGGTTCG	CASSSRDRGHYGYTF	In	VDJ	1	16	0.0035484586382789974	0.005184705119896306	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	0	3	2	0	22	36	-1	38	50	TCRBV07,TCRBV11													CASSSRDRGHYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AAGRAGACWCRGCWSYGTATCTCTGCGCCAGCAGCAAAGAGCGGGACGTGGAAGCTTTCTTTGGACAA	CASSKERDVEAFF	In	VDJ	1	18	0.003992015968063872	0.005832793259883344	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	7	3	8	0	4	23	-1	46	40	50	TCRBV01,TCRBV23													CASSKERDVEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*02	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCCGACATTGGTCAAACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	18	0.003992015968063872		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	7	2	6	5	1	16	23	32	37	33	53	TCRBV09,TCRBV12													X+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAACAAGTTTCGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSEQVSGANVLTF	In	VDJ	1	19	0.00421379463295631	0.006156837329876863	45	TCRBV06						TCRBJ02	TCRBJ02-06	01	2	4	6	4	0	7	23	-1	40	38	47		TCRBV06-01,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEQVSGANVLTF+TCRBV06-X+TCRBJ02-06	TCRBV06		TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCTATTTACCAGGACAGCTACTACAATGAGCAGTTCTTCGGGCCA	CSAPIYQDSYYNEQFF	In	VDJ	1	20	0.004435573297848747	0.0064808813998703824	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	1	5	3	11	3	26	35	52	46	55		TCRBV20-01,TCRBV20-or09_02												CSAPIYQDSYYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ACGACTCGGCCMTGTATCKCTGTGCCAGCAGCTTAGGGGCTAGCGGACGCTACGAGCAGTACTTCGGGCCG	CASSLGASGRYEQYF	In	VDJ	1	20	0.004435573297848747	0.0064808813998703824	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	4	5	3	3	3	18	34	44	37	47	TCRBV05,TCRBV07					01,02								CASSLGASGRYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAAGCATTGTCCTTTAGGTGCATAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	21	0.004657351962741184		52	TCRBV03						TCRBJ01	TCRBJ01-04	01	5	5	4	4	14	4	26	38	55	52	59		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCCCCCGCCAGGGTACTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	21	0.004657351962741184		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	4	3	3	9	2	26	34	48	43	50		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAAGCGGGAGCAAATCCTACAATGAGCAGTTCTTCGGGCCA	CASSLSGSKSYNEQFF	In	VDJ	1	23	0.005100909292526059	0.007453013609850939	48	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	6	2	1	0	4	22	-1	45	37	49		TCRBV12-03,TCRBV12-04												CASSLSGSKSYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGCAGGGGAAGGCAGAGACCCAGTACTTCGGGCCA	CSARGQGKAETQYF	In	VDJ	1	24	0.0053226879574184965	0.007777057679844459	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	4	2	4	2	5	26	39	47	41	52		TCRBV20-01,TCRBV20-or09_02												CSARGQGKAETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGAAGCATCTGTCCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	24	0.0053226879574184965		40	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	6	7	6	2	7	22	34	39	36	46		TCRBV12-03,TCRBV12-04				01,02								X+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCGGACCCAGGGGGCTGTAGGGAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	24	0.0053226879574184965		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	4	0	4	5	7	18	30	43	35	50	TCRBV07,TCRBV11													X+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTYRGKGACTCWGCTGTGTAYTTCTGTGCCAGCAGTAGGACTAGCGGGATGACAGCTGAGCAGTTCTTCGGGCCA	CASSRTSGMTAEQFF	In	VDJ	1	25	0.005544466622310933	0.008101101749837978	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	1	3	9	2	7	26	37	51	39	58	TCRBV03,TCRBV12													CASSRTSGMTAEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGGACTCSGCCGTGTATSTCTGTGCCAGCAGCGACCGGACTAGCGCCGTACACAATGAGCAGTTCTTCGGGCCA	CASSDRTSAVHNEQFF	In	VDJ	1	26	0.005766245287203371	0.008425145819831496	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	6	5	4	6	20	32	45	36	51	TCRBV07,TCRBV11					01,02								CASSDRTSAVHNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGTAGCGTCGGGGGTATGTCCTCTGGAAACACCATATATTTTGGAGAG	CASSVGGMSSGNTIYF	In	VDJ	1	26	0.005766245287203371	0.008425145819831496	48				TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-03	01	5	8	2	0	2	6	18	30	38	32	44	TCRBV11,TCRBV12	TCRBV11-03,TCRBV12-02												CASSVGGMSSGNTIYF+X+TCRBJ01-03		TCRBD02-01*01	TCRBJ01-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTGTGGGGTGCGGGCACTGAAGCTTTCTTTGGACAA	CASSLWGAGTEAFF	In	VDJ	1	26	0.005766245287203371	0.008425145819831496	42	TCRBV05			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	7	4	4	6	0	19	34	-1	40	45		TCRBV05-06,TCRBV05-07				01,02								CASSLWGAGTEAFF+TCRBV05-X+TCRBJ01-01	TCRBV05	TCRBD02-01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGTATCAAGTTGTTTCGAAAGACCTATGGCTACACCTTCGGTTCG	CSAGIKLFRKTYGYTF	In	VDJ	1	27	0.005988023952095809	0.008749189889825017	48	TCRBV20						TCRBJ01	TCRBJ01-02	01	5	2	7	4	20	0	26	35	-1	55	58		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGIKLFRKTYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCCCCTCAGGCCCCCCAGGGGATCTTAATGAAAAACTGTTTTTTGGCAGT	CASSPSGPPGDLNEKLFF	In	VDJ	1	27	0.005988023952095809	0.008749189889825017	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	2	4	13	4	19	31	50	44	54	TCRBV07,TCRBV11													CASSPSGPPGDLNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTTTCGGAAGATGGACGCTCAAGAGACCCAGTACTTCGGGCCA	CSARDFRKMDAQETQYF	In	VDJ	1	29	0.006431581281880683	0.009397278029812054	51	TCRBV20						TCRBJ02	TCRBJ02-05	01	0	1	7	2	12	3	26	40	56	52	59		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDFRKMDAQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTAAAGGGGGCCAGCTTCACAGATACGCAGTATTTTGGCCCA	CSVKGASFTDTQYF	In	VDJ	1	31	0.006875138611665558	0.010045366169799093	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	7	5	0	2	3	6	26	33	43	36	49		TCRBV20-01,TCRBV20-or09_02												CSVKGASFTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGTGACTTGGGACAGGGTAACTATGGCTACACCTTCGGTTCG	CASSDLGQGNYGYTF	In	VDJ	1	31	0.006875138611665558	0.010045366169799093	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	3	1	5	0	22	34	-1	39	48	TCRBV09,TCRBV12													CASSDLGQGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTCTGGGACTTTTGTCACGTCACCCCTCCACTTTGGGAAC	CASSSGTFVTSPLHF	In	VDJ	1	31	0.006875138611665558	0.010045366169799093	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	4	0	10	10	2	9	22	35	43	37	52		TCRBV12-03,TCRBV12-04				01,02								CASSSGTFVTSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12	TCRBD02-01	TCRBJ01-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCGGCACATCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	0.007096917276557995		43	TCRBV03						TCRBJ02	TCRBJ02-07	01	5	3	6	5	5	9	26	38	46	43	55		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACACGGGGAGCCGACTACGAGCAGTACTTCGGGCCG	CSATRGADYEQYF	In	VDJ	1	32	0.007096917276557995	0.010369410239792612	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	8	3	3	2	6	26	36	43	38	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSATRGADYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGGGGCCAGGGATCGGTAGCGACACTGAAGCTTTCTTTGGACAA	CASRGPGIGSDTEAFF	In	VDJ	1	32	0.007096917276557995	0.010369410239792612	48	TCRBV24						TCRBJ01	TCRBJ01-01	01	7	4	3	3	5	10	24	35	45	40	55		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGPGIGSDTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCTCCGGGACCAGAAGAGACCCAGTACTTCGGGCCA	CASSPPGPEETQYF	In	VDJ	1	33	0.007318695941450432	0.01069345430978613	42	TCRBV03						TCRBJ02	TCRBJ02-05	01	4	0	7	3	4	3	26	39	48	43	51		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPPGPEETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCGATGTTCCATTTTTGGCATCATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	33	0.007318695941450432		52	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	9	0	5	17	3	26	38	58	55	61		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGGGGACAGGGAGGGGTAGGCACCCAGTACTTCGGGCCA	CASRGQGGVGTQYF	In	VDJ	1	34	0.00754047460634287	0.01101749837977965	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	3	8	0	10	22	-1	42	33	52		TCRBV12-03,TCRBV12-04												CASRGQGGVGTQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD01-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTACAACTAGCGGGAGAATAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	35	0.007762253271235307		53	TCRBV05			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	3	2	0	3	4	19	33	47	36	51		TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ02-03	TCRBV05	TCRBD02-01*02	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATATAGGTGAGCAGTTCTTCGGGCCA	CASSQDIGEQFF	In	VDJ	1	39	0.008649367930805056	0.012637718729747246	36	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	5	4	9	3	0	26	43	-1	46	49		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDIGEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCTATCGGGACTAGTTTACGAGCAGTACTTCGGGCCG	CSALSGLVYEQYF	In	VDJ	1	41	0.009092925260589932	0.013285806869734284	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	8	4	6	2	26	34	48	40	50		TCRBV20-01,TCRBV20-or09_02				01,02								CSALSGLVYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCAGCCGGGGGGGCCAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	41	0.009092925260589932		43	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	5	8	0	2	6	2	26	35	49	41	51		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAAGGGGACAGGGGGACGTTCAGCCCCAGCATTTTGGTGAT	CSARGQGDVQPQHF	In	VDJ	1	45	0.00998003992015968	0.01458198314970836	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	1	6	3	4	26	34	48	37	52		TCRBV20-01,TCRBV20-or09_02												CSARGQGDVQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCCCCGGGCAGGGGTAATTCACCCCTCCACTTTGGGAAC	CSARAPGRGNSPLHF	In	VDJ	1	45	0.00998003992015968	0.01458198314970836	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	1	4	2	6	7	0	26	39	-1	46	52		TCRBV20-01,TCRBV20-or09_02												CSARAPGRGNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD01-01*01	TCRBJ01-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCCCCTCTACTTCAGGGGGAAGTCGCGAGCAGTACTTCGGGCCG	CSAPPSTSGGSREQYF	In	VDJ	1	51	0.011310711909514305	0.016526247569669476	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	1	6	13	6	26	35	55	48	61		TCRBV20-01,TCRBV20-or09_02												CSAPPSTSGGSREQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGTCAGCAAGCTTACAATGAGCAGTTCTTCGGGCCA	CSARGQQAYNEQFF	In	VDJ	2	57	0.012641383898868928	0.01847051198963059	42	TCRBV20						TCRBJ02	TCRBJ02-01	01	1	4	5	4	2	6	26	39	44	41	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARGQQAYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACTCGGGAGCGGCCTACGAGCAGTACTTCGGGCCG	CASSQDSGAAYEQYF	In	VDJ	2	59	0.013084941228653803	0.01911860012961763	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	8	2	2	2	3	23	40	48	42	51	TCRBV01,TCRBV04													CASSQDSGAAYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACAAGTTTCCATTTACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	2	64	0.01419383455311599		55	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	3	6	5	13	5	26	40	56	53	61		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAACGGGACAGGGGGCTTGGAATGAGCAGTTCTTCGGGCCA	CSARTGQGAWNEQFF	In	VDJ	2	66	0.014637391882900865	0.02138690861957226	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	0	7	2	4	26	38	52	40	56		TCRBV20-01,TCRBV20-or09_02												CSARTGQGAWNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCACCGGACTAGCGGGAACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSTGLAGTGANVLTF	In	VDJ	2	69	0.015302727877578177	0.02235904082955282	51	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	5	1	3	2	3	1	26	38	53	41	54		TCRBV03-01,TCRBV03-02												CASSTGLAGTGANVLTF+TCRBV03-X+TCRBJ02-06	TCRBV03	TCRBD02-01*02	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGACCTCATTGGGGCCTACGAGCAGTACTTCGGGCCG	CSADLIGAYEQYF	In	VDJ	2	70	0.015524506542470614	0.02268308489954634	39	TCRBV20						TCRBJ02	TCRBJ02-07	01	5	6	2	2	9	0	26	35	-1	44	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSADLIGAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGGCACGCTTCCATTTCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	2	74	0.016411621202040365		49	TCRBV03						TCRBJ02	TCRBJ02-07	01	5	9	0	5	0	20	26	-1	41	38	61		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTAGATAGTCCTGGCAATGAGCAGTTCTTCGGGCCA	CASSLDSPGNEQFF	In	VDJ	2	75	0.0166333998669328	0.024303305249513935	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	5	8	6	1	6	19	35	39	36	45	TCRBV07,TCRBV11					01,02								CASSLDSPGNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCTAGCGGGCACGTAGCATACAATGAGCAGTTCTTCGGGCCA	CSARPSGHVAYNEQFF	In	VDJ	2	77	0.017076957196717677	0.024951393389500972	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	4	4	1	9	26	38	47	39	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSARPSGHVAYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCGGACGGGCGCGGCACAGATACGCAGTATTTTGGCCCA	CSARSDGRGTDTQYF	In	VDJ	2	77	0.017076957196717677	0.024951393389500972	45	TCRBV20						TCRBJ02	TCRBJ02-03	01	2	1	7	1	2	7	26	38	44	40	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARSDGRGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTATCGGGGAGGCTCCGGAAACACCATATATTTTGGAGAG	CSASYRGGSGNTIYF	In	VDJ	2	84	0.018629407850964737	0.027219701879455604	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	3	9	1	4	6	4	26	37	49	43	53		TCRBV20-01,TCRBV20-or09_02												CSASYRGGSGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD02-01*02	TCRBJ01-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGCAACGCATCCATCATCAACCCCAGCATTTTGGTGAT		Out	VDJ	2	87	0.01929474384564205		43	TCRBV03						TCRBJ01	TCRBJ01-05	01	5	3	7	10	3	14	26	38	43	41	57		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTAAGTGGGTTGCCGAATGAGCAGTTCTTCGGGCCA	CASSLSGLPNEQFF	In	VDJ	3	91	0.0201818585052118	0.02948801036941024	42	TCRBV03						TCRBJ02	TCRBJ02-01	01	4	0	9	7	5	6	26	39	47	44	53		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSGLPNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGCACGGAGCACTAGCACAGATACGCAGTATTTTGGCCCA	CASSVARSTSTDTQYF	In	VDJ	3	91	0.0201818585052118	0.02948801036941024	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	5	7	0	1	10	24	36	41	37	51	TCRBV09,TCRBV21					unresolved								CASSVARSTSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAGGGCTAGCGGGAATGACCAAAAACATTCAGTACTTCGGCGCC	CASSLGLAGMTKNIQYF	In	VDJ	3	97	0.02151253049456642	0.031432274789371356	51	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	1	4	3	2	2	4	26	42	53	44	57		TCRBV12-03,TCRBV12-04												CASSLGLAGMTKNIQYF+TCRBV12-X+TCRBJ02-04	TCRBV12	TCRBD02-01*02	TCRBJ02-04*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGTTGCCTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	3	109	0.02417387447327567		38	TCRBV24						TCRBJ02	TCRBJ02-03	01	5	10	0	2	2	2	24	37	41	39	43		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGCCGGATATCTCATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	3	123	0.027278775781769793		41	TCRBV03						TCRBJ01	TCRBJ01-05	01	5	1	8	5	3	6	26	38	44	41	50		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACCGGGACTCCTTGCTAACTATGGCTACACCTTCGGTTCG	CSAREPGLLANYGYTF	In	VDJ	4	132	0.02927478376580173	0.04277381723914452	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	0	10	0	3	5	26	40	49	43	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREPGLLANYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTTATCAGGACAGGGGGATCAGCCCCAGCATTTTGGTGAT	CASSLSGQGDQPQHF	In	VDJ	1	14	0.003104901308494123	0.004536616979909268	45	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	1	1	5	1	0	23	40	-1	41	51													Vb 14	CASSLSGQGDQPQHF+TCRBV27-01+TCRBJ01-05	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTACGACAGGGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CSATTGANTGELFF	In	VDJ	1	11	0.002439565313816811	0.0035644847699287103	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	2	2	0	4	0	25	32	-1	36	44													Vb 4	CSATTGANTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGGAAGCGGGAGTGGGAACATTCAGTACTTCGGCGCC	CSGSGSGNIQYF	In	VDJ	1	17	0.003770237303171435	0.005508749189889825	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	7	6	2	7	2	4	25	32	42	34	46													Vb 4	CSGSGSGNIQYF+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-04*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTGGGACAGGGGGGCCTTTGGGCTGAAGCTTTCTTTGGACAA	CSVVGQGGLWAEAFF	In	VDJ	1	18	0.003992015968063872	0.005832793259883344	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	1	6	1	9	25	35	47	36	56													Vb 4	CSVVGQGGLWAEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACCCCTGGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	21	0.004657351962741184		37	TCRBV06	unresolved					TCRBJ02	TCRBJ02-03	01	2	0	10	5	4	0	23	38	-1	42	44		TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
SGACTCRGCYRTGTATCKCTGTGCCAGCAGCTTGTCTGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	22	0.004879130627633622		47	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	2	6	5	4	5	19	33	41	37	46		TCRBV07-05,TCRBV07-07												X+TCRBV07-X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGCAGGGACGGCCGTTCACAGCCCCAGCATTTTGGTGAT	CASSRDGRSQPQHF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	42	TCRBV02	TCRBV02-01	01				TCRBJ01	TCRBJ01-05	01	6	0	7	7	2	9	23	34	41	36	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASSRDGRSQPQHF+TCRBV02-01+TCRBJ01-05	TCRBV02-01*01		TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTTGGAGCACAGGGGGTGAAGCTTTCTTTGGACAA	CASSWSTGGEAFF	In	VDJ	1	14	0.003104901308494123	0.004536616979909268	39	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	1	7	6	0	23	35	-1	41	49													Vb 22	CASSWSTGGEAFF+TCRBV02-01+TCRBJ01-01	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGACTCGGGACGGGGGATACGCAGTATTTTGGCCCA	CASRLGTGDTQYF	In	VDJ	1	28	0.006209802616988246	0.009073233959818535	39	TCRBV02	TCRBV02-01	01				TCRBJ02	TCRBJ02-03	01	6	0	7	6	4	4	23	34	43	38	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 22	CASRLGTGDTQYF+TCRBV02-01+TCRBJ02-03	TCRBV02-01*01		TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCGCCCCCGATGACAGAGACAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	16	0.0035484586382789974		41	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	2	5	7	9	3	26	35	49	44	52														X+TCRBV06-07+TCRBJ01-05	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTGACTCAGGAGACTAGCGGGGGGGGCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	22	0.004879130627633622		55	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	2	0	1	4	1	26	43	61	47	62														X+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGAAACGGATCTGGGGCCAATGTCCTGACTTTCGGGGCC		Out	VDJ	1	21	0.004657351962741184		44	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	7	0	13	9	4	26	40	54	49	58			01,02										Vb 12	X+TCRBV10-01+TCRBJ02-06	TCRBV10-01	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTGGCGGGGGGTCGCAATGAGCAGTTCTTCGGGCCA	CASSLVAGGRNEQFF	In	VDJ	1	12	0.0026613439787092482	0.0038885288399222295	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	1	7	1	6	2	3	18	34	44	36	47														CASSLVAGGRNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAAGGGTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLEGSGANVLTF	In	VDJ	1	13	0.0028831226436016855	0.004212572909915748	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	0	5	3	1	0	0	18	-1	-1	35	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGSGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCCTCCACACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	15	0.00332667997338656		43	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	8	3	6	5	4	7	18	27	34	31	41														X+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-06*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTGCCGGGACAGGGGGCGGTGGAGCAGTACTTCGGGCCG	CASSLPGQGAVEQYF	In	VDJ	1	24	0.0053226879574184965	0.007777057679844459	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	0	7	5	4	18	30	47	35	51														CASSLPGQGAVEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGGGCGGCATGGGGGGGAGGACCCAGTACTTCGGGCCA	CASSLEGGMGGRTQYF	In	VDJ	1	24	0.0053226879574184965	0.007777057679844459	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	9	0	7	9	2	18	35	51	44	53														CASSLEGGMGGRTQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTCAGTGGGCAGGGAGATACGCAGTATTTTGGCCCA	CASSLSGQGDTQYF	In	VDJ	1	29	0.006431581281880683	0.009397278029812054	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	3	5	9	0	18	30	-1	39	44														CASSLSGQGDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAATCCCGACAGGGGGGCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	16	0.0035484586382789974		43	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	2	1	2	5	1	20	30	44	35	45														X+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-05*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCATCGACAGGCGGTTGGGCTTAGTATGGCTACACCTTCGGTTCG		Out	VDJ	1	17	0.003770237303171435		50	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	4	5	5	13	20	31	42	36	55														X+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCGAAGAGGGGACAGGTGGCAACGAGCAGTACTTCGGGCCG		Out	VDJ	1	17	0.003770237303171435		46	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	4	5	6	5	20	33	47	39	52														X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAGCGTCAACCGCTACTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	18	0.003992015968063872		43	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	4	9	3	10	0	20	34	-1	44	47						01,02								X+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
ACACGGCACTGTATCTCTGCGCCAGCAGTCCTTCGCTCCCAGACTAGCGGGAGGAAGAAACGGGCAAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	98	0.02173430915945886		64	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	2	1	7	11	12	17	30	54	41	66														X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTATCGGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	11	0.002439565313816811		37	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	8	5	4	1	0	23	37	-1	38	41						01,02								X+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAGGGACAGGTCCACAGATACGCAGTATTTTGGCCCA	CASSYRDRSTDTQYF	In	VDJ	1	20	0.004435573297848747	0.0064808813998703824	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	4	2	1	2	23	38	47	39	49														CASSYRDRSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCATAGCAGGGGTCAGGGAATAAGCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	25	0.005544466622310933		53	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	2	2	5	13	23	35	46	40	59														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACCAGGACAGCTAACTATGGCTACACCTTCGGTTCG	CASSYSTRTANYGYTF	In	VDJ	1	25	0.005544466622310933	0.008101101749837978	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	5	0	5	0	23	40	-1	45	51														CASSYSTRTANYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCATAGCCTTGAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	28	0.006209802616988246		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	5	7	0	4	6	23	34	42	38	48						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCATCAGGGCGCGGCACTGAAGCTTTCTTTGGACAA	CASSASGRGTEAFF	In	VDJ	1	48	0.010645375914836993	0.015554115359688918	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	3	4	4	5	23	35	44	39	49														CASSASGRGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGGGGGGGGTAACCGCCTACGAGCAGTACTTCGGGCCG	CASSGGVTAYEQYF	In	VDJ	1	20	0.004435573297848747	0.0064808813998703824	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	9	0	2	0	7	24	-1	42	35	49													Vb 18	CASSGGVTAYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-07*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATAACGCGTGCATTTGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	39	0.008649367930805056		49	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-02	01	5	2	7	4	18	0	24	36	-1	54	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01		TCRBJ01-02*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGCTCGGGACAGGGAACACTGAAGCTTTCTTTGGACAA	CASSLGTGNTEAFF	In	VDJ	1	49	0.01086715457972943	0.015878159429682438	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	4	1	4	0	24	35	-1	39	47													Vb 18	CASSLGTGNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGAGTAGCGGGACCTTCATAGATACGCAGTATTTTGGCCCA	CASSPSSGTFIDTQYF	In	VDJ	2	87	0.01929474384564205	0.028191834089436162	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	5	3	5	3	7	24	38	49	41	56													Vb 18	CASSPSSGTFIDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-03*01	4160A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				161	110	50	0	0	124	86	37	1	0	4509	3086	1409	14	0	0.0494560078	6.10844755	0.0515368432	6.59579897				8320	0.0153811797	0.0427738167	0.0321579054	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:27	Age (Range):24-45 Years (Middle Adulthood),Age:34 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 658,pfs censored status:pfs censored status 0,progression free survival (days):progression free survival (days) 658,type of chemo:carbo/taxol x 1, carbo/docetaxel x 5	0.6832297950421963	MSKCC- Snyder- P01-02		128.0	
